Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | SCD | O00767 | 2/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4346128 | 0.90 | MEN1 (0.47) | PTGDR2MEN1KMT2ALMNAHTT | |
| SCHEMBL4342690 | 0.88 | PPARG (0.48) | MEN1KMT2ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL4327189 | 0.88 | PPARG (0.48) | MEN1KMT2ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL4337063 | 0.87 | PTGDR2 (0.44) | PTGDR2MEN1KMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL4328778 | 0.84 | GAA (0.47) | PTGDR2MEN1KMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL4341654 | 0.84 | PPARG (0.48) | PTGDR2MEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL4329788 | 0.84 | POLB (0.51) | SMN1; SMN2LMNAMAPTPPARGPPARA | |
| SCHEMBL4348594 | 0.84 | MEN1 (0.49) | MEN1KMT2ASMN1; SMN2ALDH1A1PPARG | |
| SCHEMBL4329951 | 0.84 | PTGDR2 (0.39) | PTGDR2MEN1KMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL4335537 | 0.83 | KMT2A (0.58) | MEN1KMT2ASMN1; SMN2LMNAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | GPR119, IRS1, SLC5A1 | PTGDR2 3133/4885MEN1 4091/4885KMT2A 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.